FDMT (STOCKS)
4D Molecular Therapeutics, Inc. Common Stock
$9.770000
+0.110000 (+1.14%)
Prev close: $9.660000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David H. Kirn
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $499.03M
- Employees
- 227
- P/E (TTM)
- -3.84
- P/B (TTM)
- 1.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.43 | $-0.78 | +1.2077 | +155.29% |
|
Sep 2025 (Q3)
|
$-1.01 | $-1.00 | -0.0118 | -1.18% |
|
Jun 2025 (Q2)
|
$-0.98 | $-0.89 | -0.0867 | -9.71% |
|
Mar 2025 (Q1)
|
$-0.86 | $-0.88 | +0.0195 | +2.22% |
Financial Statements
| Revenues | $85.21M |
| Benefits Costs and Expenses | $225.32M |
| Costs And Expenses | $225.32M |
| Nonoperating Income/Loss | $19.44M |
| Operating Expenses | $244.76M |
| Depreciation and Amortization | $4.69M |
| Other Operating Expenses | $240.06M |
| Operating Income/Loss | -$159.55M |
| Income/Loss From Continuing Operations After Tax | -$140.11M |
| Income/Loss From Continuing Operations Before Tax | -$140.11M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$140.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$140.11M |
| Net Income/Loss Available To Common Stockholders, Basic | -$140.11M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.42 |
| Diluted Earnings Per Share | -$2.42 |
| Basic Average Shares | 57,930,180 |
| Diluted Average Shares | 57,930,180 |
| Assets | $566.71M |
| Current Assets | $413.13M |
| Cash | $514.00M |
| Noncurrent Assets | $153.58M |
| Fixed Assets | $14.87M |
| Other Non-current Assets | $138.71M |
| Liabilities | $61.05M |
| Current Liabilities | $43.99M |
| Accounts Payable | $11.16M |
| Wages | $13.81M |
| Other Current Liabilities | $19.02M |
| Noncurrent Liabilities | $17.06M |
| Equity | $505.66M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $505.66M |
| Liabilities And Equity | $566.71M |
| Net Cash Flow From Operating Activities | -$109.08M |
| Net Cash Flow From Operating Activities, Continuing | -$109.08M |
| Net Cash Flow From Investing Activities | -$92.97M |
| Net Cash Flow From Investing Activities, Continuing | -$92.97M |
| Net Cash Flow From Financing Activities | $112.96M |
| Net Cash Flow From Financing Activities, Continuing | $112.96M |
| Net Cash Flow | -$89.10M |
| Net Cash Flow, Continuing | -$89.10M |
| Comprehensive Income/Loss | -$139.61M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$139.61M |
| Other Comprehensive Income/Loss | $498.00K |